Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia

Journal of Clinical Psychopharmacology

Volumn 20, Issue 3, 2000, Pages 357-361

  Wassef, Adel A ^a,e   Dott, Sharon G ^b,c   Harris, Ann ^b   Brown, Alston ^b   O'Boyle, Michael ^b   Meyer III, Walter J ^b   Rose, Robert M ^d  

^a University of Texas Harris County Psychiatric Center   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c Gulf Coast Mental Hlth Mental R   (United States)

^d John D and Catherine T MacArthur Foundation   (United States)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; VALPROATE SEMISODIUM; VALPROIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GABA AGONISTS; HALOPERIDOL; HUMANS; MALE; PILOT PROJECTS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; VALPROIC ACID;

EID: 0034127343     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200006000-00011     Document Type: Article

References (14)

1. Wassef A, Dott S, Harris A, Brown A, O'Boyle M, Meyer W, Rose R. Critical review of GABA-ergic drugs in the treatment of schizophrenia. J Clin Psychopharmacol 1999;19:222-32.
2. Spitzer RL, Endicott J, Robin E. Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry 1978;35:773-82.
3. Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorder and schizophrenia. Arch Gen Psychiatry 1978;35: 837-44.
4. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1963;10:799-812.
5. Andreasen NC. Negative symptoms in schizophrenia, definition and reliability. Arch Gen Psychiatry 1982;39:784-8.
6. Nagao T, Ohshimo T, Mitsunobu K, Sato M, Otsuki S. Cerebrospinal fluid monoamine metabolites and cyclic nucleotides in chronic schizophrenic patients with tardive dyskinesia or drug-induced tremor. Biol Psychiatry 1979;14:509-23.
7. Linnoila M, Viukari M, Hietala O. Effect of sodium valproate on tardive dyskinesia. Br J Psychiatry 1976;129:114-9.
8. Altamura AC, Basile R, Mauri M, Cazzullo CL. Valpromide (Depamide) in the treatment of acute psychotic states: open clinical study [article in French]. Acta Psychiatr Belg 1986;86:297-304.
9. Morinigo A, Martin J, Gonzalez S, Mateo I. Treatment of resistant schizophrenia with valproate and neuroleptic drugs. Hillside J Clin Psychiatry 1989;11:199-207.
10. Gündürewa V, Beckmann H, Zimmer R, Rüther E. Effect of VPA on schizophrenic syndromes. Arzneimittelforschung Drug Res 1980;30:1212-3.
11. Ko GN, Korpi ER, Freed WJ, Zalcman SJ, Bigelow LB. Effect of valproic acid on behavior and plasma amino acid concentrations in chronic schizophrenic patients. Biol Psychiatry 1985;20:209-15.
12. McElroy SL, Keck PE Jr, Pope HG Jr. Sodium valproate: its use in primary psychiatric disorders. J Clin Psychopharmacol 1987;7: 16-24.
13. Lautin A, Angrist B, Stanley M, Gershon S, Heckl K, Karobath M. Sodium valproate in schizophrenia: some biochemical correlates. Br J Psychiatry 1980;137:240-4.
14. Wolkowitz O, Pickar D. Benzodiazepines in the treatment of schizophrenia: a review and appraisal. Am J Psychiatry 1991;148: 714-26.